Exclusive Financial Advisor to Sanderling Ventures on Sale of Intellectual Property

2005—Completed the sale of a substantial portion of the intellectual property for Genteric, Inc., a seed stage developer of therapeutic protein drugs, to Altor BioScience Corporation in exchange for stock.  Sanderling, and several other leading biotech and healthcare venture capitalists, engaged our team to sell Genteric, Inc., one of their portfolio companies, and/or its intellectual property. The company’s novel approach to therapeutic protein delivery, although promising, was still several years away from commercial development.

“This was a complicated and time consuming transaction involving several different moving parts including the sale of the IP, a large patent portfolio, and re-negotiation of necessary licenses from several leading Universities,” said Dr. Mitchell Finer, CEO of Intracel Holdings Corporation and former CEO of Genteric, Inc.”